At 8.0% CAGR, Europe Arterial Blood Gas Kits Market is Projected to be worth US$ 3,79,422.25 thousand by 2031, says Business Market Insights

According to Business Market Insights’ research, the Europe arterial blood gas kits market was valued at US$ 2,05,474.54 thousand in 2023 and is expected to reach US$ 3,79,422.25 thousand by 2031, recording a CAGR of 8.0% from 2023 to 2031. Surging adoption of point-of-care diagnostics in emerging countries and increasing incidence of respiratory diseases are among the critical factors attributed to drive the Europe arterial blood gas kits market growth.

The inability to run rapid diagnoses is a significant cause of deaths resulting from various diseases in emerging countries. An effective diagnostic infrastructure requires stable electrical power, sophisticated instruments, expensive reagents, and highly trained professionals; thus, diagnoses in developing countries are often limited by the unavailability of these resources. Moreover, the existing diagnostic capabilities result in long assay times, rendering them unsuitable for settings with limited resource availability. Point-of-care testing offers immediate diagnostic results at or near the patient's location, enabling rapid clinical decision-making, streamlined workflows, and enhanced patient outcomes. The need for timely interventions, efficient diagnostic processes, and personalized healthcare delivery fuels the demand for decentralized testing solutions. Point-of-care arterial blood gas kits allow healthcare providers to perform critical diagnostic tests at the patient's bedside, in emergency departments, or in remote settings, facilitating on-the-spot assessment of blood gas parameters, electrolyte levels, and acid–base status. The accessibility and immediacy of point-of-care analyzers empower clinicians to promptly initiate appropriate treatments, monitor patient responses in real time, and optimize clinical decision-making in acute care scenarios. The shift toward point-of-care diagnostics also drives technological advancements in arterial blood gas kits as manufacturers focus on developing compact, automated, and easy-to-use devices that deliver accurate and fast results. The seamless integration of point-of-care analyzers into healthcare workflows enhances operational efficiency, reduces turnaround times for results, and improves the overall quality of patient care. Thus, as healthcare settings embrace the advantages of point-of-care testing, the demand for portable and user-friendly arterial blood gas kits is rising in developing countries, which is likely to create growth opportunities for the market in the coming years.

On the contrary, the high cost of kits and complications associated with arterial blood sampling aids hamper the growth of Europe arterial blood gas kits market.

Based on syringe type, the Europe arterial blood gas kits market is bifurcated into luer slip syringe and luer lock syringe. The luer lock syringe segment held 58.0% market share in 2023, amassing US$ 1,19,266.87 thousand. It is projected to garner US$ 2,25,496.44 thousand by 2031 to register 8.3% CAGR during 2023–2031.

In terms of type, the Europe arterial blood gas kits market is bifurcated into vented and non-vented. The vented segment held 64.4% share of Europe arterial blood gas kits market in 2023, amassing US$ 1,32,285.55 thousand. It is anticipated to garner US$ 2,51,079.40 thousand by 2031 to expand at 8.3% CAGR during 2023–2031.

By usage, the Europe arterial blood gas kits market is bifurcated into pre-set plunger mode and manual aspiration. The pre-set plunger mode segment held 75.9% share of Europe arterial blood gas kits market in 2023, amassing US$ 1,55,873.95 thousand. It is projected to garner US$ 2,93,566.55 thousand by 2031 to expand at 8.2% CAGR from 2023 to 2031.

Based on application, the Europe arterial blood gas kits market is bifurcated into in vitro diagnostics and electrolyte analysis. The in vitro diagnostics segment held 72.5% share of Europe arterial blood gas kits market in 2023, amassing US$ 1,48,973.24 thousand. It is predicted to garner US$ 2,84,518.74 thousand by 2031 to expand at 8.4% CAGR between 2023 and 2031. The in vitro diagnostics segment held a larger market share in 2023. Furthermore, the in vitro diagnostics segment is sub segmented into pH blood gas, oxygen content, and others.

In terms of needle gauge, the Europe arterial blood gas kits market is segmented into less than 23G, 23G to 25G, and greater than 25G. The 23G to 25G segment held 49.0% share of Europe arterial blood gas kits market in 2023, amassing US$ 1,00,778.17 thousand. It is estimated to garner US$ 1,92,699.59 thousand by 2031 to expand at 8.4% CAGR during 2023–2031.

Based on syringe volume, the Europe arterial blood gas kits market is segmented into 1ml, 3ml, and others. The 3ml segment held 48.0% share of Europe arterial blood gas kits market in 2023, amassing US$ 98,535.19 thousand. It is projected to garner US$ 1,88,022.75 thousand by 2031 to expand at 8.4% CAGR from 2023 to 2031.

By end user, the Europe arterial blood gas kits market is categorized into hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics segment held 56.6% share of Europe arterial blood gas kits market in 2023, amassing US$ 1,16,274.02 thousand. It is projected to garner US$ 2,21,512.66 thousand by 2031 to expand at 8.4% CAGR from 2023 to 2031.

Based on country, the Europe arterial blood gas kits market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 22.5% share of Europe arterial blood gas kits market in 2023. It was assessed at US$ 46,252.32 thousand in 2023 and is likely to hit US$ 88,239.03 thousand by 2031, registering a CAGR of 8.4% during 2023 to 2031.

Key players operating in the Europe arterial blood gas kits market are Radiometer Medical ApS, Vyaire Medical Inc, Siemens Healthineers AG, AdvaCare Pharma USA LLC, Becton Dickinson and Co, ICU Medical Inc, SARSTEDT AG & Co KG, and Lepu Medical Technology Beijing Co Ltd., among others.

• In March 2024, BD partnered with Odense University Hospital, the Health Innovation Centre of Southern Denmark, the Danish Technological Institute, the Global Material & Asset Fund, and EcoFITT ApS to conduct a feasibility study on recycling used blood collection tubes made from high-quality polyethylene terephthalate (PET) plastic. The study demonstrated that these tubes can be cleaned, shredded, and molded into new products. The Region of Southern Denmark funded the collaborative effort and is part of a broader initiative to advance Denmark's Climate Action Strategy. The strategy aims to reduce the country's greenhouse gas emissions by 70 percent in 2030 compared to 1990.
• In January 2022, ICU Medical acquired Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. Combined with ICU Medical's existing businesses, the two companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion. The NeoCord ABG kit includes two labels and samplers to accommodate venous and arterial draws.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com